ORIC
Oric Pharmaceuticals, Inc. - Common Stock$8.96Price Chart
Quant Score History
0 weakest · 5 strongestTechnical Indicators
RSI (14)
33.3
Dividends & Splits
Ex-Dividend
No dividend history.
Split
No splits on record.
Company Overview
Statement fields are the latest reported fiscal year (FY2025 FY), not a rolling TTM.
Market Cap
882.82M
P/E
-6.10
Fwd P/E
-6.02
P/B
3.63
P/S
—
EV/Rev
—
Div Yield
—
Div/Share
—
Revenue (FY)
—
Net Income (FY)
-129.47M
EPS (FY)
-1.47
Profit Margin
—
ROE
-53.25%
ROA
-31.99%
52W High
14.68
52W Low
7.23
50D MA
12.75
200D MA
11.24
Shares Out
98.53M
Analyst Target
21.64
Factor Grades
BuyValue
Growth
Profit.
Momentum
EPS Rev.
Quant Score: 3.0 / 5
Model score computed from reported data. Not a recommendation.
Risk & Return
Ann. Return
38.57%
Volatility
87.70%
Sharpe
0.37
Beta
—
Alpha
—
Max Drawdown
66.03%
VaR (95%)
6.94%
Sortino
0.54
Upcoming Earnings
News
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Opens in a new tab ↗Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
Opens in a new tab ↗ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
Opens in a new tab ↗ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Opens in a new tab ↗ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
Opens in a new tab ↗ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Opens in a new tab ↗Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
Opens in a new tab ↗ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Opens in a new tab ↗Analysed Articles
15 scoredMean
-0.07
Bullish
1
Neutral
12
Bearish
2
Polarity of crawled news items tagged to this symbol.